Mouse CD300a/LMIR1 APC-conjugated Antibody Summary
Leu28-Arg183
Accession # BAC80268
Applications
Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.
Scientific Data
Detection of CD300a/LMIR1 in T1165 Mouse Cell Line by Flow Cytometry. T1165 mouse plasmacytoma cell line was stained with Rat Anti-Mouse CD300a/LMIR1 APC-conjugated Monoclonal Antibody (Catalog # FAB1186A, filled histogram) or isotype control antibody (Catalog # IC006A, open histogram). View our protocol for Staining Membrane-associated Proteins.
Reconstitution Calculator
Preparation and Storage
Background: CD300a/LMIR1
CD300a, also known as LMIR1, CMRF-35H, IRp60, CLM-8, and MAIR-I, is a 60 kDa glycoprotein member of the immunoglobulin superfamily (1). Mouse CD300a consists of a 158 amino acid (aa) extracellular domain (ECD) with one Ig-like V-type domain, a 21 aa transmembrane segment, and a 112 aa cytoplasmic domain that contains three immunoreceptor tyrosine-based inhibitory motifs (ITIMs) and a non-canonical ITIM (2, 3). Within the ECD, mouse CD300a shares 40% and 66% aa sequence identity with human and rat CD300a, respectively. Alternate splicing generates an additional mouse CD300a isoform with a 4 aa deletion following the Ig-like domain (3). In mouse, CD300a is expressed on peripheral eosinophils, mast cells, neutrophils, dendritic cells, macrophages, and some B cells (2‑4). Antibody cross‑linking of CD300a induces phosphorylation of tyrosine residues in the cytoplasmic domain. This leads to the recruitment of phosphatases SHIP, SHP-1, and SHP-2 and inhibition of NK cell, eosinophil, and mast cell activation (2, 3, 5‑7). Cross‑linking of CD300a to other surface proteins such as SCF R or Fc epsilon RI on mast cells, Fc gamma RIIA on neutrophils, or CCR3 on mast cells and eosinophils inhibits downstream signaling from those receptors (4, 8‑10). CD300a cross‑linking also limits the in vivo activities of these cells with a subsequent reduction of allergic inflammation symptoms (4, 7, 9).
- Clark, G.J. et al. (2009) Trends Immunol. 30:209.
- Kumagai, H. et al. (2003) Biochem. Biophys. Res. Commun. 307:719.
- Yotsumoto, K. et al. (2003) J. Exp. Med. 198:223.
- Munitz, A. et al. (2006) J. Allergy Clin. Immunol. 118:1082.
- Cantoni, C. et al. (1999) Eur. J. Immunol. 29:3148.
- Munitz, A. et al. (2006) Blood 107:1996.
- Bachelet, I. et al. (2005) J. Immunol. 175:7989.
- Bachelet, I. et al. (2008) J. Immunol. 180:6064.
- Bachelet, I. et al. (2006) J. Allergy Clin. Immunol. 117:1314.
- Alvarez, Y. et al. (2008) Mol. Immunol. 45:253.
Product Datasheets
FAQs
No product specific FAQs exist for this product, however you may
View all Antibody FAQsReviews for Mouse CD300a/LMIR1 APC-conjugated Antibody
There are currently no reviews for this product. Be the first to review Mouse CD300a/LMIR1 APC-conjugated Antibody and earn rewards!
Have you used Mouse CD300a/LMIR1 APC-conjugated Antibody?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image